ST诺泰跌2.45%，成交额2.76亿元，后市是否有机会？

Core Viewpoint - ST诺泰 is experiencing a decline in stock price and trading volume, with a market capitalization of 13.201 billion yuan as of September 4, 2023 [1] Group 1: Company Developments - The company has received clinical trial approval for its self-developed GLP-1 receptor agonist SPN0103-009 injection for diabetes and weight loss [2] - ST诺泰's custom product business primarily focuses on CDMO (Contract Development and Manufacturing Organization), emphasizing the integration of high-tech process development and large-scale production capabilities [2] - The company’s Thymosin Alpha 1 injection is used for the treatment of chronic hepatitis B [3] - The approval of Oseltamivir Phosphate capsules for treating and preventing influenza in adults and children has been granted, with the approval valid until May 30, 2027 [3] Group 2: Financial Performance - As of the 2024 annual report, overseas revenue accounts for 63.12% of total revenue, benefiting from the depreciation of the RMB [4] - For the first half of 2025, ST诺泰 achieved revenue of 1.048 billion yuan, a year-on-year increase of 26.07%, and a net profit attributable to shareholders of 310 million yuan, up 36.49% year-on-year [8] Group 3: Market Activity - The stock has seen a net outflow of 20.1232 million yuan from main funds today, with a continuous reduction in main fund positions over the past three days [5][6] - The average trading cost of the stock is 43.39 yuan, with the current price near a resistance level of 42.60 yuan, indicating potential for a price correction or upward movement if the resistance is broken [7] Group 4: Shareholder Information - As of June 30, the number of shareholders for ST诺泰 is 18,800, an increase of 45.66% from the previous period, with an average of 16,772 circulating shares per person, a decrease of 1.66% [8] Group 5: Dividend Information - ST诺泰 has distributed a total of 362 million yuan in dividends since its A-share listing, with 330 million yuan distributed over the past three years [9]